Investigational drug · Phase 3
Timolol eye drops 0.5%
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glaucoma, Ocular Hypertension.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
142
Any phase or sponsor naming "Timolol eye drops 0.5%"
First trial start
2025
Jun 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Timolol eye drops 0.5%", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glaucoma
- Ocular Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Timolol eye drops 0.5%" as an intervention, largest first.
- Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02207621 · 756 participants · Start Jul 2014 · Primary completion Mar 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol maleate Ophthalmic Solution 0.5% BID and 1 more · For: Ocular Hypertension; Open-angle Glaucoma
Sites: Bedminster, New Jersey
AllerganAbbVie (ABBV)
NCT02571712 · 750 participants · Start Nov 10, 2015 · Primary completion Jun 21, 2018
Drug: bimatoprost 0.03% plus timolol 0.5% · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
- Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02558374 · 708 participants · Start Sep 2015 · Primary completion Dec 2016
Drug: AR-13324 Ophthalmic Solution 0.02%; Timolol Maleate Ophthalmic Solution 0.5% BID · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01026831 · 643 participants · Start Jan 6, 2010 · Primary completion Sep 17, 2010
Drug: Preservative-Free Tafluprost; Comparator: timolol · For: Open-angle Glaucoma; Ocular Hypertension
- Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension PatientsPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00651612 · 604 participants · Start Nov 2005 · Primary completion Jan 2007
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution; Concurrent brimonidine 0.2% and 0.5% timolol · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%Pivotal-lookingCompleted
Glaukos CorporationIndustry
NCT03519386 · 590 participants · Start Jul 26, 2018 · Primary completion Apr 5, 2022
Drug: Sham surgery + active-comparator eye drops · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Sioux Falls, South Dakota
- Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01177098 · 561 participants · Start Oct 2010 · Primary completion Feb 2012
Drug: bimatoprost /timolol formulation A fixed combination ophthalmic solution; bimatoprost/timolol fixed combination ophthalmic solution · For: Glaucoma; Ocular Hypertension
Sites: Artesia, California; Sydney, Australia; Brno, Czechia · 9 sites in all
- Clinical Study Comparing Two Models of a Travoprost Intraocular ImplantPivotal-lookingCompleted
Glaukos CorporationIndustry
NCT03868124 · 560 participants · Start Sep 17, 2018 · Primary completion Jun 10, 2022
Drug: Sham surgery + active-comparator eye drops · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Las Vegas, Nevada
Alcon ResearchIndustry
NCT00519753 · 522 participants · Start Aug 2007 · Primary completion Dec 2008
Drug: Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav) · For: Glaucoma
Sites: Mainz, Germany
- Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantPivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT07495852 · 510 participants (planned) · Start Feb 17, 2026 · Primary completion Jun 2028
Drug: Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5% · For: Glaucoma
Sites: Dothan, Alabama
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Glaucoma
- Bimatoprost Implant SystemPhase 33 trials
SpyGlass Pharma, Inc. · Cataract, Glaucoma, Ocular Hypertension
- Gen 2 Travoprost Intracameral ImplantGen 2 Travoprost Intraocular ImplantPhase 32 trials
Glaukos Corporation · Glaucoma
- Inactive controlQLS-111 vehiclePhase 32 trials
Can-Fite BioPharma · Hepatocellular Carcinoma, Cirrhosis, Open-angle Glaucoma (OAG)
- QLS-111Phase 23 trials
Qlaris Bio, Inc. · Normal Tension Glaucoma (NTG), Glaucoma, Open-angle Glaucoma (OAG)
- BL1107Phase 22 trials
Bausch & Lomb Incorporated · Dry Eye Disease, Glaucoma
- ASP2767Phase 21 trial
Astellas · Glaucoma
- intraocular implant releasing timololTimoD implantPhase 21 trial
EyeD Pharma · Glaucoma, Ocular Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.